UA81251C2 - Method of controlled ovarian hyperstimulation and pharmaceutical kit for use in such method - Google Patents
Method of controlled ovarian hyperstimulation and pharmaceutical kit for use in such method Download PDFInfo
- Publication number
- UA81251C2 UA81251C2 UAA200500168A UA2005000168A UA81251C2 UA 81251 C2 UA81251 C2 UA 81251C2 UA A200500168 A UAA200500168 A UA A200500168A UA 2005000168 A UA2005000168 A UA 2005000168A UA 81251 C2 UA81251 C2 UA 81251C2
- Authority
- UA
- Ukraine
- Prior art keywords
- recombinant
- fsh
- substance
- ganirelix
- dose
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 39
- 206010033266 Ovarian Hyperstimulation Syndrome Diseases 0.000 title claims abstract description 10
- 238000007920 subcutaneous administration Methods 0.000 claims abstract description 44
- 108700032141 ganirelix Proteins 0.000 claims abstract description 22
- 229960003794 ganirelix Drugs 0.000 claims abstract description 22
- GJNXBNATEDXMAK-PFLSVRRQSA-N ganirelix Chemical compound C([C@@H](C(=O)N[C@H](CCCCN=C(NCC)NCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN=C(NCC)NCC)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 GJNXBNATEDXMAK-PFLSVRRQSA-N 0.000 claims abstract description 22
- 230000002028 premature Effects 0.000 claims abstract description 22
- 230000021121 meiosis Effects 0.000 claims abstract description 15
- 210000002700 urine Anatomy 0.000 claims abstract description 11
- 230000007812 deficiency Effects 0.000 claims abstract description 9
- 238000011260 co-administration Methods 0.000 claims abstract description 7
- 208000024891 symptom Diseases 0.000 claims abstract description 6
- 102000009151 Luteinizing Hormone Human genes 0.000 claims description 103
- 108010073521 Luteinizing Hormone Proteins 0.000 claims description 103
- 229940040129 luteinizing hormone Drugs 0.000 claims description 103
- 108700008462 cetrorelix Proteins 0.000 claims description 23
- 229960003230 cetrorelix Drugs 0.000 claims description 23
- SBNPWPIBESPSIF-MHWMIDJBSA-N cetrorelix Chemical compound C([C@@H](C(=O)N[C@H](CCCNC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 SBNPWPIBESPSIF-MHWMIDJBSA-N 0.000 claims description 23
- 230000002485 urinary effect Effects 0.000 claims description 18
- 230000029849 luteinization Effects 0.000 claims description 14
- 230000037396 body weight Effects 0.000 claims description 11
- 241000124008 Mammalia Species 0.000 claims description 10
- 210000001161 mammalian embryo Anatomy 0.000 claims description 10
- 230000018109 developmental process Effects 0.000 claims description 6
- 230000005906 menstruation Effects 0.000 claims description 6
- 210000002394 ovarian follicle Anatomy 0.000 claims description 6
- 235000013601 eggs Nutrition 0.000 claims description 5
- 230000004720 fertilization Effects 0.000 claims description 5
- 210000002966 serum Anatomy 0.000 claims description 5
- 210000004291 uterus Anatomy 0.000 claims description 5
- 230000004936 stimulating effect Effects 0.000 claims description 4
- 101100120663 Drosophila melanogaster fs(1)h gene Proteins 0.000 claims 13
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000002269 spontaneous effect Effects 0.000 claims 1
- 238000012876 topography Methods 0.000 claims 1
- 239000000126 substance Substances 0.000 abstract description 80
- 239000005557 antagonist Substances 0.000 abstract description 42
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 abstract description 40
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 abstract description 40
- 229940028334 follicle stimulating hormone Drugs 0.000 abstract description 40
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 abstract description 13
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 abstract description 13
- 229940035638 gonadotropin-releasing hormone Drugs 0.000 abstract description 13
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 abstract description 12
- 230000003054 hormonal effect Effects 0.000 abstract description 5
- 239000002474 gonadorelin antagonist Substances 0.000 abstract description 2
- 229940088597 hormone Drugs 0.000 abstract description 2
- 239000005556 hormone Substances 0.000 abstract description 2
- 229940121381 gonadotrophin releasing hormone (gnrh) antagonists Drugs 0.000 abstract 2
- 230000008217 follicular development Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 230000001592 luteinising effect Effects 0.000 abstract 1
- 238000002513 implantation Methods 0.000 description 14
- 238000002560 therapeutic procedure Methods 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 238000003070 Statistical process control Methods 0.000 description 10
- 230000035935 pregnancy Effects 0.000 description 10
- 239000000556 agonist Substances 0.000 description 9
- 210000000287 oocyte Anatomy 0.000 description 9
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 102000006771 Gonadotropins Human genes 0.000 description 5
- 108010086677 Gonadotropins Proteins 0.000 description 5
- 229940011871 estrogen Drugs 0.000 description 5
- 239000000262 estrogen Substances 0.000 description 5
- 239000002622 gonadotropin Substances 0.000 description 5
- 229940094892 gonadotropins Drugs 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 102000011022 Chorionic Gonadotropin Human genes 0.000 description 4
- 108010062540 Chorionic Gonadotropin Proteins 0.000 description 4
- 206010062767 Hypophysitis Diseases 0.000 description 4
- 230000002411 adverse Effects 0.000 description 4
- 230000016087 ovulation Effects 0.000 description 4
- 210000003635 pituitary gland Anatomy 0.000 description 4
- 230000008901 benefit Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004246 corpus luteum Anatomy 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 210000001672 ovary Anatomy 0.000 description 3
- 230000027758 ovulation cycle Effects 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 229960003387 progesterone Drugs 0.000 description 3
- 239000000186 progesterone Substances 0.000 description 3
- 229940015047 chorionic gonadotropin Drugs 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000002503 granulosa cell Anatomy 0.000 description 2
- 229940084986 human chorionic gonadotropin Drugs 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 208000000509 infertility Diseases 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 231100000535 infertility Toxicity 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000009027 insemination Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- PYTMYKVIJXPNBD-OQKDUQJOSA-N 2-[4-[(z)-2-chloro-1,2-diphenylethenyl]phenoxy]-n,n-diethylethanamine;hydron;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C1=CC(OCCN(CC)CC)=CC=C1C(\C=1C=CC=CC=1)=C(/Cl)C1=CC=CC=C1 PYTMYKVIJXPNBD-OQKDUQJOSA-N 0.000 description 1
- 208000007984 Female Infertility Diseases 0.000 description 1
- 101000818510 Homo sapiens Zinc-activated ligand-gated ion channel Proteins 0.000 description 1
- 206010021928 Infertility female Diseases 0.000 description 1
- 208000007466 Male Infertility Diseases 0.000 description 1
- 102000006877 Pituitary Hormones Human genes 0.000 description 1
- 108010047386 Pituitary Hormones Proteins 0.000 description 1
- 102100021143 Zinc-activated ligand-gated ion channel Human genes 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 229940046836 anti-estrogen Drugs 0.000 description 1
- 230000001833 anti-estrogenic effect Effects 0.000 description 1
- 230000002513 anti-ovulatory effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229940046989 clomiphene citrate Drugs 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000011262 co‐therapy Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 231100000547 follicle rupture Toxicity 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- -1 heterocyclic low molecular weight compounds Chemical class 0.000 description 1
- 239000000960 hypophysis hormone Substances 0.000 description 1
- 208000021267 infertility disease Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000005541 medical transmission Effects 0.000 description 1
- 239000012907 medicinal substance Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 208000025661 ovarian cyst Diseases 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000000541 pulsatile effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- FQZYTYWMLGAPFJ-OQKDUQJOSA-N tamoxifen citrate Chemical compound [H+].[H+].[H+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 FQZYTYWMLGAPFJ-OQKDUQJOSA-N 0.000 description 1
- 229960003454 tamoxifen citrate Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Pregnancy & Childbirth (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gynecology & Obstetrics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02077221 | 2002-06-07 | ||
| PCT/NL2003/000370 WO2003103770A2 (en) | 2002-06-07 | 2003-06-06 | Method of controlled ovarian hyperstimulation and pharmaceutical kit for use in such method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA81251C2 true UA81251C2 (en) | 2007-12-25 |
Family
ID=29724462
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA200500168A UA81251C2 (en) | 2002-06-07 | 2003-06-06 | Method of controlled ovarian hyperstimulation and pharmaceutical kit for use in such method |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US7815912B2 (ja) |
| EP (1) | EP1511537B1 (ja) |
| JP (1) | JP2005530818A (ja) |
| KR (1) | KR20050058285A (ja) |
| CN (1) | CN1684737A (ja) |
| AU (1) | AU2003274929B2 (ja) |
| BR (1) | BR0305033A (ja) |
| CA (1) | CA2488719A1 (ja) |
| EA (1) | EA009371B1 (ja) |
| ES (1) | ES2399962T3 (ja) |
| IL (1) | IL165522A0 (ja) |
| IS (1) | IS7586A (ja) |
| ME (1) | MEP39308A (ja) |
| MX (1) | MXPA04012246A (ja) |
| NO (1) | NO20045304L (ja) |
| NZ (1) | NZ536984A (ja) |
| PL (1) | PL373991A1 (ja) |
| RS (1) | RS105004A (ja) |
| UA (1) | UA81251C2 (ja) |
| WO (1) | WO2003103770A2 (ja) |
| ZA (1) | ZA200409857B (ja) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE602008001783D1 (de) * | 2007-01-08 | 2010-08-26 | Pantarhei Bioscience Bv | Verfahren zur behandlung oder prävention von unfruchtbarkeit bei weiblichen säugern und pharmazeutisches kit zur anwendung dieses verfahrens |
| EP2734239A2 (en) | 2011-07-18 | 2014-05-28 | Arts Biologics A/S | Long acting luteinizing hormone (lh) compound |
| US9216037B2 (en) | 2013-06-21 | 2015-12-22 | Previvo Genetics, Llc | Uterine lavage for embryo retrieval |
| US20150272622A1 (en) | 2011-12-22 | 2015-10-01 | Previvo Genetics, Llc | Recovery and processing of human embryos formed in vivo |
| US9282995B2 (en) * | 2011-12-22 | 2016-03-15 | Previvo Genetics, Llc | Recovery and processing of human embryos formed in vivo |
| WO2018015497A2 (en) | 2016-07-21 | 2018-01-25 | ObsEva S.A. | Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage |
| CA3149898A1 (en) | 2019-09-03 | 2021-03-11 | Ernest Loumaye | Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage |
| CA3167121A1 (en) | 2020-02-10 | 2021-08-19 | ObsEva S.A. | Biomarkers for oxytocin receptor antagonist therapy |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0788799A3 (en) * | 1996-02-07 | 1998-10-21 | ASTA Medica Aktiengesellschaft | LHRH-Antagonists in the treatment of fertility disorders |
| CN1199642A (zh) * | 1997-05-16 | 1998-11-25 | Asta药物股份公司 | 治疗不育症的lhrh－拮抗剂 |
| EP0994718B1 (en) | 1997-06-20 | 2005-08-17 | Akzo Nobel N.V. | Gonadotropin releasing hormone antagonist |
| AU752415B2 (en) * | 1998-04-23 | 2002-09-19 | Zentaris Ivf Gmbh | Method for the treatment of fertility disorders |
| EP1156822B1 (en) * | 1999-02-24 | 2006-02-08 | Novo Nordisk A/S | Iin vitro method for synchronisation of oocyte maturation |
| CA2341974A1 (en) * | 1999-06-23 | 2001-01-04 | Akzo Nobel Nv | Gonadotropin releasing hormone antagonist |
| US20030092628A1 (en) * | 1999-06-23 | 2003-05-15 | De Greef Henrik Johan Matthieu Maria | Gonadotropin releasing hormone antagonist |
| PT1434600E (pt) * | 2001-09-12 | 2009-04-28 | Serono Lab | Utilização de hl em hiperestimulação ovariana controlada |
| DE60223284T2 (de) | 2001-12-21 | 2008-07-31 | Pantarhei Bioscience B.V. | Verfahren zur regulierten hyperstimulation der eierstöcke und pharmazeutischen kit zur verwendung in diesem verfahren |
-
2003
- 2003-06-06 RS YUP-1050/04A patent/RS105004A/sr unknown
- 2003-06-06 KR KR1020047019890A patent/KR20050058285A/ko not_active Application Discontinuation
- 2003-06-06 US US10/517,028 patent/US7815912B2/en not_active Expired - Fee Related
- 2003-06-06 BR BR0305033-5A patent/BR0305033A/pt not_active IP Right Cessation
- 2003-06-06 CA CA002488719A patent/CA2488719A1/en not_active Abandoned
- 2003-06-06 NZ NZ536984A patent/NZ536984A/en unknown
- 2003-06-06 UA UAA200500168A patent/UA81251C2/uk unknown
- 2003-06-06 EP EP03741621A patent/EP1511537B1/en not_active Expired - Lifetime
- 2003-06-06 WO PCT/NL2003/000370 patent/WO2003103770A2/en active Application Filing
- 2003-06-06 JP JP2004510888A patent/JP2005530818A/ja active Pending
- 2003-06-06 PL PL03373991A patent/PL373991A1/xx not_active Application Discontinuation
- 2003-06-06 ES ES03741621T patent/ES2399962T3/es not_active Expired - Lifetime
- 2003-06-06 AU AU2003274929A patent/AU2003274929B2/en not_active Ceased
- 2003-06-06 MX MXPA04012246A patent/MXPA04012246A/es unknown
- 2003-06-06 ME MEP-393/08A patent/MEP39308A/xx unknown
- 2003-06-06 CN CNA038183900A patent/CN1684737A/zh active Pending
- 2003-06-06 EA EA200401619A patent/EA009371B1/ru not_active IP Right Cessation
-
2004
- 2004-12-02 IL IL16552204A patent/IL165522A0/xx unknown
- 2004-12-03 IS IS7586A patent/IS7586A/is unknown
- 2004-12-03 NO NO20045304A patent/NO20045304L/no not_active Application Discontinuation
- 2004-12-06 ZA ZA200409857A patent/ZA200409857B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EA200401619A1 (ru) | 2005-06-30 |
| CN1684737A (zh) | 2005-10-19 |
| RS105004A (en) | 2007-02-05 |
| AU2003274929B2 (en) | 2008-04-10 |
| WO2003103770A3 (en) | 2004-04-22 |
| PL373991A1 (en) | 2005-09-19 |
| KR20050058285A (ko) | 2005-06-16 |
| JP2005530818A (ja) | 2005-10-13 |
| EP1511537B1 (en) | 2012-11-21 |
| IS7586A (is) | 2004-12-03 |
| CA2488719A1 (en) | 2003-12-18 |
| WO2003103770A2 (en) | 2003-12-18 |
| EA009371B1 (ru) | 2007-12-28 |
| IL165522A0 (en) | 2006-01-15 |
| ES2399962T3 (es) | 2013-04-04 |
| MXPA04012246A (es) | 2005-04-08 |
| NZ536984A (en) | 2008-01-31 |
| NO20045304L (no) | 2005-02-07 |
| US20050235374A1 (en) | 2005-10-20 |
| AU2003274929A1 (en) | 2003-12-22 |
| BR0305033A (pt) | 2004-11-09 |
| US7815912B2 (en) | 2010-10-19 |
| ZA200409857B (en) | 2006-02-22 |
| MEP39308A (en) | 2011-02-10 |
| EP1511537A2 (en) | 2005-03-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8236785B2 (en) | Method of treating or preventing infertility in a female mammal and pharmaceutical kit for use in such method | |
| Huirne et al. | Effect of an oral contraceptive pill on follicular development in IVF/ICSI patients receiving a GnRH antagonist: a randomized study | |
| US7405197B2 (en) | Use of hCG in controlled ovarian hyperstimulation | |
| UA81251C2 (en) | Method of controlled ovarian hyperstimulation and pharmaceutical kit for use in such method | |
| EP1455831B1 (en) | Method of controlled ovarian hyperstimulation and pharmaceutical kit for use in such method | |
| ES2356895T3 (es) | USO DE LA hCG Y LH EN LA HIPERESTIMULACIÓN OVÁRICA CONTROLADA. | |
| AU2002331939B2 (en) | Use of LH in controlled ovarian hyperstimulation | |
| ES2217113T5 (es) | Uso de fsh para tratar infertilidad. | |
| McCue | Hormone Therapy in Cycling Mares | |
| Nagori et al. | 6 Intrauterine Insemination | |
| Meridis et al. | Drugs in reproductive medicine | |
| Huirne et al. | Effect of an OC pill on follicular development in IVF/ICSI patients receiving a GnRH antagonist: a randomized study | |
| Ron-El R et al. | Characteristics of very short regimens | |
| Adaniya et al. | Use of a Microdose Gonadotropin Releasing Hormone Agonist (GnRH-a) Stimulation Protocol in Assisted Reproductive Technology (ART) Patients with Poor Ovarian Response |